PARSIPPANY, N.J., Oct. 29 /PRNewswire/ -- Ferring Pharmaceuticals Inc. announces the appointment of Harry F. Kovelman, MD as Associate Medical Director for Orthopaedics. Dr. Kovelman will be responsible for medical affairs for EUFLEXXA®( ) (1% sodium hyaluronate), a treatment for knee pain due to osteoarthritis, as well as Ferring's expanding line of orthopaedic products.
"Dr. Kovelman is exceptionally well qualified to fill this role," said Edward Trott, MD, Vice President, Medical Affairs. "His experience and knowledge in the field of orthopaedic medicine will provide valuable insight as we continue to build upon our success with EUFLEXXA®."
Dr. Kovelman joins Ferring with a broad range of experience in medical affairs, business development, sales and marketing in the medical and orthopaedic device industries. Prior to joining Ferring, Dr. Kovelman was Director of Medical Affairs at Otto Bock HealthCare, which provides equipment for restorative health. He has also served as Chief Executive Officer of Archimedes Medical Technology, a consulting services company for the medical device industry; Executive Director, Orthopaedic Institute of St. Joseph Medical Center in Maryland; and Medical Affairs Director and Vice President of Sales and Marketing at Dynasplint Systems, Inc., manufacturer of medical devices for range-of-motion loss.
Dr. Kovelman received his Doctor of Medicine degree from the Universidad Del Noreste in Mexico, and Bachelor of Science degree in psychology from the University of Maryland.
About EUFLEXXA®( )
EUFLEXXA®( ) (1% sodium hyaluronate) is the first non-avian derived* hyaluronic acid (HA) approved in the U.S. for treatment of knee pain due to osteoarthritis (OA). EUFLEXXA® is indicated for patients who have failed to get adequate pain relief either from simple pain medications, such as acetaminophen, or from exercise and/or physical therapy. The process used to manufacture EUFLEXXA® results in highly-purified HA with properties similar to the HA in healthy human synovial fluid.(1-4) EUFLEXXA® received approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004 and became available to the public on November 8, 2005. For more information, visit www.EUFLEXXA.com.
EUFLEXXA® should not be used in people who have had any previous allergic reaction to hyaluronate preparations or who have knee joint infections or skin diseases in the area of the injection site. Common adverse events reported were arthralgia (joint pain) and back pain. Temporary knee pain and swelling may occur after injection. Strict aseptic technique must be followed to avoid joint infection.
About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of infertility, urology, and orthopaedic products in the U.S. market. They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR®( )and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, 100 mg, FIRMAGON®( ) (degarelix for injection), PROSED® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA® (1% sodium hyaluronate).
Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.
*Derived through bacterial fermentation
(1) Data on File, Ferring Pharmaceuticals.
(2) ( )Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006; 14:154-162.
(3) ( )Schiavinato A, Finesso M, Cortivo R, & Abatangelo G (2002). Comparison of the effects of intra-articular injections of Hyaluronan and its chemically cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clin Exp Rheumatol 20, 445-454.
(4) Goomer RS, Leslie K, Maris T, & Amiel D (2005). Native hyaluronan produces less hypersensitivity than cross-linked hyaluronan. Clin Orthop Relat Res 239-245.
SOURCE Ferring Pharmaceuticals Inc.
|SOURCE Ferring Pharmaceuticals Inc.|
Copyright©2009 PR Newswire.
All rights reserved